ChipCare raises $5 mln to take blood-testing technology to remote locales
ChipCare Corp has secured $5.045 million in a Series A round, bringing its total funding to date to $8.3 million. The latest deal was led by U.S.-based Puffin Partners and was joined by new and existing investors, including MaRS Innovation, Maple Leaf Angels, Winfield Venture Group, Epic Capital, and a number of angel investors. Based in Toronto, ChipCare has developed a handheld, blood-testing platform for HIV and other infectious and non-communicable diseases. Its technology, which is currently being commercialized, is targeted to remote health settings. The company's first HIV-related test, which aims to link people with HIV with treatments, is expected to hit the market late next year.
3 March 2015•4 mins read
